Literature DB >> 7047670

Gain/loss of poly(Glu50Tyr50)/poly(Glu60Ala30Tyr10) responsiveness in the bm12 mutant strain.

H Y Lei, R W Melvold, S D Miller, C Waltenbaugh.   

Abstract

The development of inbred strains of mutant mice has proven useful in ascribing specific gene functions to particular genetic loci within the regions and subregions of the H-2 complex. The B6.C-H-2bm12 (bm12) strain is of particular interest in that, compared to parental C57Bl/6Kh (B6) mice, it bears a presumptive single gene mutation altering the Ab beta chain encoded by the I-A subregion. Our data show that bm12 mice have gained the ability to respond to poly(Glu50Tyr50)(GT) and have lost the ability to make plaque-forming cell or delayed-type hypersensitivity responses to the closely related copolymer, poly(Glu60Ala30Tyr10)(GAT), although retaining the ability to mount a GAT-specific T cell proliferative response. This is in sharp contrast to the parental B6 strain, which is a GT nonresponder and a GAT responder. Thus, this study is the first to report the establishment of responder status as a consequence of mutation. Possible mechanisms accounting for the gain/loss of GT/GAT responsiveness in the context of a two-step helper T cell model are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047670      PMCID: PMC2186774          DOI: 10.1084/jem.156.2.596

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

1.  B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse.

Authors:  I F McKenzie; G M Morgan; M S Sandrin; M M Michaelides; R W Melvold; H I Kohn
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

Review 2.  The immune response genes of the major histocompatibility complex.

Authors:  B Benacerraf; R N Germain
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

3.  Genetic control of specific immune responses and immune suppressions by I-region genes.

Authors:  B Benacerraf; M E Dorf
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1977

4.  Characterization of the primary IgM response to GAT and GT: conditions required for the detection of IgM antibodies.

Authors:  C Waltenbaugh; A Dessein; B Benacerraf
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

5.  Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice.

Authors:  G Corradin; H M Etlinger; J M Chiller
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

6.  Immunosuppressive factor(s) specific for L-glutamic acid50-L-tyrosine50 (GT). III. Generation of suppressor T cells by a suppressive extract derived from GT-primed lymphoid cells.

Authors:  C Waltenbaugh; J Thèze; J A Kapp; B Benacerraf
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

7.  Suppressor T-cell activity in responder X nonresponder (C57BL/10 X DBA/1)F1 spleen cells responsive to L-glutamic acid60-L-alanine30-L-tyrosine10.

Authors:  C W Pierce; J A Kapp
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

8.  Antigen-specific T cell-mediated suppression. V. H-2-linked genetic control of distinct antigen-specific defects in the production and activity of L-glutamic acid50-L-tyrosine50 suppressor factor.

Authors:  R N Germain; C Waltenbaugh; B Benacerraf
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

9.  Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGlu)-poly(DLAla)--poly(LLys). II. Evidence for a T-T-cell collaboration in delayed-type hypersensitivity responses and for a T-cell defect at the efferent phase in nonresponder H-2k mice.

Authors:  G Strassmann; Z Eshhar; E Mozes
Journal:  J Exp Med       Date:  1980-03-01       Impact factor: 14.307

10.  The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells.

Authors:  S D Miller; R P Wetzig; H N Claman
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

View more
  8 in total

1.  Distinct regulation of humoral and cellular immunities to hepatitis B surface antigen.

Authors:  H Y Lei; S C Lee; C K Yu
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

2.  Mechanisms of genetic control of immune responses. II. Nonresponsiveness in BALB/c GT-specific cell-mediated immune responses does not correlate with the absence of functional T cells or the induction of suppressor T cells.

Authors:  M K Kennedy; M K Jenkins; S D Miller
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

3.  Igh allotype-linked control of immune complex-type hypersensitivity induced by hepatitis B surface antigen.

Authors:  H Y Lei; S C Lee
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

4.  Mechanisms of genetic control of immune responses. I. Evidence for distinct multi-step helper T-cell pathways in cellular and humoral responses to GAT.

Authors:  S D Miller; R W Melvold; C Waltenbaugh
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

5.  The murine bm12 gene conversion provides evidence that T cells recognize predominantly Ia conformation.

Authors:  H Y Tse; S Kanamori; W D Walsh; T H Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

6.  Hepatitis B surface antigen induces an early-type hypersensitivity.

Authors:  H Y Lei; J Y Wang; T T Chang; C C Wang
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

7.  Regulation of immune responses by I-J gene products. VI. Recognition of I-E molecules by I-J-bearing suppressor factors.

Authors:  C Waltenbaugh; L Sun; H Y Lei
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

8.  DNA sequence analysis of I-Ak beta mutants reveals serologically immunodominant region.

Authors:  B N Beck; L R Pease; M P Bell; J M Buerstedde; A E Nilson; G G Schlauder; D J McKean
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.